Decreased blood levels of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV)
Article
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
Patients with systemic lupus erythematosus (SLE) show an enhanced risk to develop human papillomavirus (HPV) infection, and aggressive forms of this condition are seen in these patients. The aim of this study was to assess the possible relationship among HPV infection, immunosuppressive therapy and levels of leukocyte subsets in patients with SLE. The following individuals were included in the study: (1) SLE patients under immunosuppressive therapy and with lesions caused by HPV (n = 16); (2) SLE patients under immunosuppressive therapy and no evidence of HPV infection (n = 20); (3) untreated SLE patients with no evidence of HPV infection (n = 7), and; (4) healthy female subjects without evidence of HPV infection (n = 10). Peripheral blood was obtained and the percentages of different lymphocyte subsets were determined by flow cytometry, with the use of the following monoclonal antibodies: CD3, CD4, CD8, CD16, CD19, CD20, CD22, CD56, and CD335 (NKp46). We found that SLE patients under immunosuppressive therapy and with lesions caused by HPV showed significantly lower levels of B lymphocytes and NK cells compared to other groups. In contrast, SLE patients receiving immunosuppressive drugs and with no evidence of HPV infection showed similar levels of B and NK cells than healthy controls. Those patients receiving mycophenolate mofetil (MMF) had a diminished number of B cells, and a positive correlation was detected between the dose of MMF and the number of HPV skin lesions. Our data suggest that therapy of SLE patients with MMF is associated with diminished levels of B and NK cells and an enhanced risk for HPV infection. © 2012 Springer-Verlag.
publication date
published in
Research
keywords
-
B lymphocytes; Human papillomavirus; Immunosuppressive drugs; NK cells; Systemic lupus erythematosus azathioprine; CD16 antibody; CD19 antibody; CD20 antibody; CD22 antibody; CD3 antibody; CD335 antibody; CD4 antibody; CD56 antibody; CD8 antibody; hydroxychloroquine; immunosuppressive agent; methotrexate; monoclonal antibody; mycophenolic acid 2 morpholinoethyl ester; natural cytotoxicity triggering receptor 1; prednisone; simvastatin; unclassified drug; adult; article; B lymphocyte; blood analysis; cell loss; clinical article; clinical assessment; controlled study; disease association; dose response; drug effect; female; flow cytometry; human; immunosuppressive treatment; infection risk; low drug dose; lymphocyte subpopulation; male; natural killer cell; papillomavirus infection; priority journal; risk assessment; systemic lupus erythematosus; viral skin disease; Adult; B-Lymphocytes; Blood Circulation; Female; Humans; Immunity, Cellular; Immunosuppressive Agents; Killer Cells, Natural; Lupus Erythematosus, Systemic; Lymphocyte Count; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Young Adult
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue